Literature DB >> 12214035

Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms.

Yu Xia1, Tsunao Saitoh, Kenji Uéda, Seigo Tanaka, Xiaohua Chen, Makoto Hashimoto, Leigh Hsu, Chris Conrad, Mary Sundsmo, Makoto Yoshimoto, Leon Thal, Robert Katzman, Eliezer Masliah.   

Abstract

The human NACP/alpha-synuclein gene has been cloned. This gene consists of 6 exons ranging in size from 42 to 1110 bp. The translation start codon ATG is encoded by exon 2 and the stop codon TAA is encoded by exon 6. The non-Abeta component of Alzheimer's disease amyloid (NAC) is encoded by exon 4. The two previously reported minor isoforms of NACP/alpha-synuclein, NACP112 [29] and NACP126 [6], are alternatively spliced products, in which exon 5 and exon 3 are spliced out, respectively. Exon 1 was found to have different splicing sites, producing different 5'-untranslated sequences in the cDNAs. A previously reported dinucleotide repeat polymorphic marker has been mapped to 8kb upstream of the transcription start site. A highly TC-rich sequence in intron 4 was found to be polymorphic by length and four alleles, A0, A1, A2 and B have been identified in the Caucasian population. Genotyping this polymorphism among pure Alzheimer's, Lewy body variant and Parkinson's subjects and aged normal control subjects did not reveal any significant differences.

Entities:  

Year:  2001        PMID: 12214035     DOI: 10.3233/jad-2001-3508

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  19 in total

1.  NACP-Rep1 relates to Beck Depression Inventory scores in healthy humans.

Authors:  Bernd Lenz; Christiane Sysk; Norbert Thuerauf; Marion Clepce; Karin Reich; Helge Frieling; Georg Winterer; Stefan Bleich; Johannes Kornhuber
Journal:  J Mol Neurosci       Date:  2011-01-27       Impact factor: 3.444

2.  Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.

Authors:  Ahmad Jowaed; Ina Schmitt; Oliver Kaut; Ullrich Wüllner
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 3.  E3 ubiquitin ligases in protein quality control mechanism.

Authors:  Deepak Chhangani; Ajay Prakash Joshi; Amit Mishra
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

4.  The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.

Authors:  Jack T Rogers; Sohan Mikkilineni; Ippolita Cantuti-Castelvetri; Deborah H Smith; Xudong Huang; Sanghamitra Bandyopadhyay; Catherine M Cahill; Maria L Maccecchini; Debomoy K Lahiri; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2011-01-08       Impact factor: 3.575

Review 5.  Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Authors:  Dena A M Amer; G Brent Irvine; Omar M A El-Agnaf
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

6.  Regulation of alpha-synuclein expression in alcohol-preferring and -non preferring rats.

Authors:  Tiebing Liang; Lucinda G Carr
Journal:  J Neurochem       Date:  2006-10       Impact factor: 5.372

Review 7.  Environmental toxins and alpha-synuclein in Parkinson's disease.

Authors:  Yanying Liu; Hui Yang
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 8.  Genetic variability in SNCA and Parkinson's disease.

Authors:  Lasse Pihlstrøm; Mathias Toft
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

Review 9.  Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.

Authors:  Adrien W Schmid; Bruno Fauvet; Marc Moniatte; Hilal A Lashuel
Journal:  Mol Cell Proteomics       Date:  2013-08-21       Impact factor: 5.911

10.  Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.

Authors:  Shasi V Kalivendi; Deepthi Yedlapudi; Cecilia J Hillard; B Kalyanaraman
Journal:  Free Radic Biol Med       Date:  2009-10-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.